Methods: IRB approved retrospective chart review was conducted looking at patients taking posaconazole and fluconazole from January 2013 to January 2014. Patients over 18 years of age with severe coccidioidomycosis were included. Patients without miliary or extra pulmonary dissemination were excluded. Efficacy was assessed using the Mycosis Study Group (MSG) score. Primary outcome was defined as the number of patients with greater than 50% decrease in MSG score. Secondary outcomes were number of patients with no change or less than 25% change in MSG score, overall change in MSG score and improvement in coccidioides complement fixation (CF) titers.5Statistical analysis was conducted using Stata v12. Wilcoxon Rank-Sum test was used for continuous data. Fischer's Exact test was used for discrete data.
Results: 46 patients were included in the study. 23 patients were taking posaconazole and 23 patients were taking fluconazole for severe coccidioidomycosis. 78% of patients in posaconazole group and 83% of patients in fluconazole group had greater than 50% decrease in MSG score (p value 0.81). There was no statistically significant differences between the two groups. 22% and 17% of patients in posaconazole and fluconazole group respectively have no change or less than 25% change in MSG score (p value 0.777). Overall change in MSG score was 8 for posaconazole and 5 for fluconazole (p value 0.01). Greater than 75% of patients in both group have decrease in coccidioides CF titers.
Conclusion: Posaconazole is an effective treatment option for severe coccidioidomycosis. Its efficacy is similar to fluconazole. It can be used in patients with more severe disease and higher MSG score at diagnosis. It can be used in patients refractory to standard treatment and in those who need oral maintenance therapy.
A. Heidari, None
R. H. Johnson, None